Abstract

Background

To investigate the safety, efficacy, and follow-up outcomes of microwave ablation (MWA) in patients with breast fibroadenoma.

Methods

An institutional review board-approved this study of patients treated with MWA for breast fibroadenoma from October 2017 to March 2019. Clinical features of patients and breast fibroadenoma were analyzed. At follow-up all patients received physical examination and ultrasound imaging.

Results

In total, 171 patients with 271 lesions were enrolled. The mean lesion diameter was 1.35 ± 0.47 cm. The results revealed differential lesion states, including stability, enlargement, reduction, and complete regression, at 1-6, 6-12, and >12 months of follow-up. The size was reduced in 22.14% (31/140), 26.36% (29/110), and 36.36% (16/44) of the lesions at 1-6, 6-12, and >12 months of follow-up, respectively. The proportion of lesions with complete regression was 24.29% (34/140) at 1-6 months, 45.45% (50/110) at 6-12 months, and 40.91% (18/44) at >12 months of follow up. There was no significant relationship between the curative effect and age, lesion location, and blood flow in patients with breast fibroadenoma after MWA (p > .05), but there was statistically significant relationship with lesion diameter (categorized as <1.5 cm and ≥1.5 cm) (p < .05).

Conclusions

The current evidence indicates that MWA is a safe and effective method for treating breast fibroadenoma. Nevertheless, further large-scale prospective trials and well-designed future studies are warranted to validate our findings.

中文翻译：

---

微波消融治疗乳腺纤维腺瘤的可行性和有效性

摘要

背景

目的探讨乳腺癌消融术中微波消融术（MWA）的安全性，有效性和随访结果。

方法

2017年10月至2019年3月，一项机构审查委员会批准了针对MWA治疗乳腺纤维腺瘤的患者的研究。分析了患者和乳腺纤维腺瘤的临床特征。随访时，所有患者均接受了体格检查和超声检查。

结果

总共招募了171例患者，有271个病灶。平均病变直径为1.35±0.47 cm。结果显示，在1-6、6-12和大于12个月的随访中，病变状态不同，包括稳定性，增大，缩小和完全消退。在1-6、6-12和> 12个月的随访中，病变的大小分别减少了22.14％（31/140），26.36％（29/110）和36.36％（16/44），分别。在1-6个月时，完全消退的病变比例为24.29％（34/140），在6-12个月时为45.45％（50/110），在> 12个月时为40.91％（18/44）。MWA后乳腺纤维腺瘤患者的疗效与年龄，病变部位和血流之间无显着相关性（p > 0.05），但与病灶直径（分类为<1.5 cm和≥1.5cm）之间存在统计学上的显着相关性（p  <.05）。

结论

目前的证据表明，MWA是治疗乳腺纤维腺瘤的一种安全有效的方法。尽管如此，仍需要进行进一步的大规模前瞻性试验和精心设计的未来研究来验证我们的发现。